TNFSF10 and cancer: Although activation of the TRAIL pathway has emerged as an attractive therapeutic strategy in cancer, and early phase 1 trials yielded encouraging preliminary data, this did not translate to significant clinical benefit in subsequent phase 2 studies [2, 3].